1. Buy or Sell at your own risk
2. Don't risk more than 1%-2% of your capital as stop loss
3. Position Size formula:- Stop Loss/(Buy Price-Initial Stop Loss Price)
4. Either sell on initial stop loss hit or when closes below weekly supertrend
After a TTM Sales and Profit growth of 11.5% and 15% respectively and after receiving an approval from the Subject Expert Committee (“SEC”) of the Central Drugs Standard Control Organization (“CDSCO”) to conduct local trials on anti Covid-19 pill Paxlovid,
CIPLA
has given a breakout with higher than average volume. The breakout came after a long consolidation since Jun'21. It's a buy with a stop loss at Rs.979.
2. Don't risk more than 1%-2% of your capital as stop loss
3. Position Size formula:- Stop Loss/(Buy Price-Initial Stop Loss Price)
4. Either sell on initial stop loss hit or when closes below weekly supertrend
After a TTM Sales and Profit growth of 11.5% and 15% respectively and after receiving an approval from the Subject Expert Committee (“SEC”) of the Central Drugs Standard Control Organization (“CDSCO”) to conduct local trials on anti Covid-19 pill Paxlovid,
CIPLA
has given a breakout with higher than average volume. The breakout came after a long consolidation since Jun'21. It's a buy with a stop loss at Rs.979.